NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

Syndax Pharmaceuticals (SNDX) Is Up 26.1% After FDA Priority Review for Revuforj and Revenue Surge

Syndax Pharmaceuticals recently reported second quarter 2025 results, showing revenues of US$37.96 million, up sharply from US$3.5 million a year earlier, and a net loss of US$71.85 million, compared with US$68.06 million previously. Alongside this earnings release, the company announced that the FDA has granted Priority Review for Revuforj’s supplemental New Drug Application in relapsed or refractory mutant NPM1 acute myeloid leukemia, highlighting expanding opportunities in its targeted...
NYSE:RVTY
NYSE:RVTYLife Sciences

How Investors May Respond To Revvity (RVTY) Launching pHSense Reagents for Drug Discovery Innovation

Earlier this month, Revvity unveiled its pHSense™ reagents, a new technology developed to improve the efficiency and accuracy of internalization studies in drug discovery, specifically for G protein-coupled receptors (GPCRs) and antibody-drug conjugates (ADCs). This platform aims to address current challenges in high-throughput screening and is positioned to meet rising demand for advanced tools in oncology and precision medicine research workflows. We'll examine how the launch of pHSense™...
NasdaqGS:MKTX
NasdaqGS:MKTXCapital Markets

Did Strong Earnings and M&A Signals Just Shift MarketAxess (MKTX) Investment Narrative?

Earlier this month, MarketAxess Holdings reported strong second quarter results with revenue rising to US$219.46 million and multiple enhancements to its electronic trading protocols, while also announcing a quarterly dividend and signaling readiness for merger and acquisition opportunities. CEO Christopher Concannon highlighted both a robust balance sheet and new executive capacity as key enablers for potential M&A, suggesting an active approach to future growth initiatives beyond...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR) Falls Deeper into Losses and Seeks $250M—Is Its Funding Model Sustainable?

Structure Therapeutics Inc. recently reported a second-quarter net loss of US$61.66 million, widening from US$26.03 million a year ago, and for the six-month period, the net loss also increased to US$108.49 million from US$52.07 million in the previous year. Following these results, the company filed for a US$250 million follow-on equity offering and a shelf registration allowing future issuance of various securities including American Depositary Shares, preferred shares, debt securities,...
NYSE:YUM
NYSE:YUMHospitality

Does Mixed Profit Trends vs Revenue Growth Shift the Long-Term Narrative for Yum! Brands (YUM)?

Yum! Brands, Inc. reported its second quarter 2025 earnings on August 5, revealing US$1.93 billion in revenue and US$374 million in net income, both higher than the same period last year. While the quarter showed stronger sales, net income for the first half of 2025 was US$628 million, down from US$681 million a year earlier, reflecting mixed profitability trends despite revenue growth. We'll now explore how these mixed profit and revenue results may affect Yum! Brands' ongoing investment...
NYSE:PWR
NYSE:PWRConstruction

How Investors Are Reacting To Quanta Services (PWR) $1.5 Billion Debt Refinancing and Maturity Extension

Earlier this month, Quanta Services completed a US$1.5 billion multi-tranche senior notes offering with maturities spanning 2028, 2031, and 2035, intending to use the proceeds to repay existing borrowings under its commercial paper program and senior credit facility. By extending its debt maturity profile and locking in fixed interest rates, Quanta Services could see changes in its financial flexibility and interest expenses, influencing its future capital allocation decisions. We'll explore...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

Why TG Therapeutics (TGTX) Is Up 5.1% After Raising 2025 Revenue Guidance and Reporting Earnings

TG Therapeutics recently reported strong second quarter results, with US$141.15 million in revenue and a sharp rise in net income, and raised its full-year 2025 revenue guidance to approximately US$585 million. The company also filed multiple shelf registrations totaling up to US$139.45 million, including an ESOP-related offering, indicating preparations for potential future capital needs alongside improving financial performance. We’ll now explore how the raised annual guidance and robust...
NYSE:FSLY
NYSE:FSLYIT

Is Fastly’s (FSLY) Leadership Shakeup and New Share Plan Shifting the Investment Case?

Fastly announced its second-quarter 2025 earnings, updated guidance, key executive appointments, including a new CFO, and a shelf registration for US$12.76 million in Class A shares for an employee stock plan. The consolidation of marketing and revenue under a new President, alongside leadership changes and fresh capital strategies, marks an important expansion of operational focus and corporate direction. We'll explore how Fastly's leadership realignment and updated guidance may influence...